Deep Brain Stimulation (DBS) systems in Dystonia is a rapidly emerging medical technology field. DBS systems are indicated as a help in the care of intractable (drug refractory) primary dystonia, chronic, including hemidystonia, segmental and/or generalised dystonia, and cervical dystonia (torticollis), in patients seven years of age or older. Because of its success and lesser risk of side effects, DBS has increasingly replaced other surgical procedures such as stereotactic thalamotomy, pallidotomy, and cervical rhizotomy. Furthermore, as compared to other treatments, these therapies may maintain progress in movements and postures as well as the ability to do everyday activities for several years.
The deep brain stimulation systems in Dystonia market is expected to witness significant growth in the coming years. This is due to the rising prevalence of dystonia, an inherited neurological disorder, growing demand for minimally invasive treatments, and the increasing availability of advanced deep brain stimulation systems. For instance, according to American Association of Neurological Surgeons, Dystonia affects around 250,000 people living in the U.S, making it the third most common movement disorder behind Parkinson's disease and essential tremor. Furthermore, the increasing number of research studies focusing on developing new therapies for dystonia are expected to create lucrative opportunities for market participants over the forecast period.
Key market players are continuously integrating unique technologies into their product lines to provide better symptomatic treatments for Dystonia patients, with reduced adverse effects. For instance,
In July 2021, Medtronic plc announced the FDA approval of the SenSight Directional Lead System for Deep Brain Stimulation (DBS) therapy, as well as the first U.S. implants. This is used to treat symptoms associated with movement disorders such as dystonia, Parkinson's disease, medically resistant epilepsy, and essential tremor.
In July 2022, the FDA has granted Abbott breakthrough device designation to research the use of its deep brain stimulation (DBS) device in treatment-resistant depression (TRD), a kind of major depressive disorder (MDD).
In September 2022, the firm that pioneered Directional Deep Brain Stimulation (DBS) in Neuromodulation, Aleva Neurotherapeutics SA, announced the CE approval of its MRI labelling for the directSTIM DBS system, to be utilised in a full-body magnetic resonance imaging (MRI) environment.
Therefore, continuous product innovations & developments in DBS devices by key players & recommendations by dystonia-specialized neurologists are expected to boost the deep brain stimulation systems in dystonia market growth over forecast period. However, limitations linked with various techniques of DBS, complex regulatory framework and lack of skilled professionals are expected to obstruct the market growth.
Leading participants in the deep brain stimulation systems in dystonia market include Medtronic, Boston Scientific Corporation, Abbott.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."